Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application.
Journal Article (Journal Article)
Newer pharmacologic agents have demonstrated significant clinical and economic benefit in high-risk percutaneous transluminal coronary angioplasty (PTCA) patients. However, the higher costs of these agents may prohibit their use in lower-risk coronary artery disease (CAD) populations. We developed a decision support system (DSS) to determine the level of clinical effectiveness these newer agents must exhibit to be either cost-neutral or cost-effective in non-ST elevation patients. Our DSS evaluated six month cumulative costs, increased years of life saved (YOLS), and lifetime cost-effectiveness. We found that these therapies can cost as much as $1500 and be cost-neutral at six months if they reduce the composite endpoint of death, myocardial infarction (MI), or revascularization by 15%, and they may cost as much as $3000 and be cost-effective if they reduce this endpoint by 10%.
Full Text
Duke Authors
Cited Authors
- Eisenstein, EL; Peterson, ED; Jollis, JG; Tardiff, BE; Califf, RM; Knight, JD; Mark, DB
Published Date
- 1997
Published In
Start / End Page
- 273 - 277
PubMed ID
- 9357631
Pubmed Central ID
- PMC2233333
International Standard Serial Number (ISSN)
- 1091-8280
Language
- eng
Conference Location
- United States